Published in Annu Rev Med on January 01, 2011
The Concise Guide to PHARMACOLOGY 2013/14: ion channels. Br J Pharmacol (2013) 3.03
CFTR: folding, misfolding and correcting the ΔF508 conformational defect. Trends Mol Med (2011) 1.99
Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol (2014) 0.94
Fixing cystic fibrosis by correcting CFTR domain assembly. J Cell Biol (2012) 0.90
Eltgol acutelly improves airway clearance and reduces static pulmonary volumes in adult cystic fibrosis patients. J Phys Ther Sci (2014) 0.84
Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1. J Immunol (2015) 0.81
Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action. Mol Pharmacol (2015) 0.80
Molecular Chaperones as Targets to Circumvent the CFTR Defect in Cystic Fibrosis. Front Pharmacol (2012) 0.79
Gene therapy for the treatment of cystic fibrosis. Appl Clin Genet (2012) 0.78
Allele frequency for Cystic fibrosis in Indians vis-a/-vis global populations. Bioinformation (2015) 0.75
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A (2009) 5.72
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A (2011) 3.87
Novel Pseudomonas aeruginosa quorum-sensing inhibitors identified in an ultra-high-throughput screen. Antimicrob Agents Chemother (2006) 2.04
A structurally unrelated mimic of a Pseudomonas aeruginosa acyl-homoserine lactone quorum-sensing signal. Proc Natl Acad Sci U S A (2006) 1.54
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat (2010) 1.40
The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev (2006) 1.19
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother (2006) 1.07
Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS One (2013) 0.83
ATM haplotypes and associated mutations in Iranian patients with ataxia-telangiectasia: recurring homozygosity without a founder haplotype. Hum Genet (2005) 0.80
Evidence that the promoter can influence assembly of antitermination complexes at downstream RNA sites. J Bacteriol (2006) 0.75